A randomized, placebo-controlled trial of rituximab in IgM MGUS patients with neuropathy and anti-MAG antibodies showed benefit in one-third of the treatment arm compared to stable disease or worsening symptoms in the placebo arm [59]. Here, CD40LG is linked to neuropathy.